During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2
Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.
Title : Interdependent antioxidant therapy in covid-19 and other critical diseases
Richard Z. Cheng, Cheng Integrative Health Center, United States
Title : Biotechnological exploration of phyto-drugs against MDR bacteria targeting DNA topoisomerase I and RNA polymerase
Asit Kumar Chakraborty, Vidyasagar University, India
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Limiting factors in implementing pharmacovigilance principles in the elderly
Hana Hassan, University of Bristol, United Kingdom
Title : Intellection of molecular drug delivery models -an ayurvedic perspective
Ashtavaidyan Dr. E.T. Krishnan Mooss, Vaidyaratnam Group , India
Title : Evaluation of the wound healing activity of Hyoscyamus nigar seed powder on the wistar albino rats
Jeevanath Ruban, Trincomalee Campus, Sri Lanka
Title : Comparison of dexmedetomidine and propofol with ketofol in sedation of candidates for cataract surgery
Alireza Kamali, Arak University of Medical Sciences, Iran (Islamic Republic of)
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : Exosome-like nanoparticles from plants: Promising pharmaceutical preparations and delivery carriers
Chongzhi Liu, The First Affiliated Hospital of Chengdu Medical College, China